| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Rafael Holdings Inc. Class B | CPI-613 (devimistat) + cytarabine + mitoxantrone - (ARMADA 2000) | Acute myeloid leukemia (AML) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Rafael Holdings Inc. Class B | CPI-613 (devimistat) + mFOLFIRINOX - (AVENGER 500) | Pancreatic Cancer | Phase 3 | Trial Completed | Intravenous | Oncology |
| Rafael Holdings Inc. Class B | Trappsol Cyclo | Alzheimer’s Disease | Phase 2b | Ongoing | Intravenous | Neurology |
| Rafael Holdings Inc. Class B | AMT-101 - (CASTRO) | Rheumatoid arthritis | Phase 2 | Ongoing | oral | Immunology: Anti-TNF |
| Rafael Holdings Inc. Class B | AMT-101 combo with with anti-TNFα - (MARKET) | Ulcerative colitis | Phase 2 | Trial Completed | Oral | Gastroenterology |
| Rafael Holdings Inc. Class B | AMT-101 - (FILLMORE) | Pouchitis | Phase 2 | Ongoing | Oral | Gastroenterology |
| Rafael Holdings Inc. Class B | AMT-101 monotherapy - (LOMBARD) | Ulcerative colitis | Phase 2 | Trial Planned | oral | Gastroenterology |
| Rafael Holdings Inc. Class B | CPI-613 (devimistat) + bendamustine | Relapsed or Refractory T - cell Lymphoma | Phase 2 | Trial Completed | Intravenous | Oncology |